The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | Highlights from the lymphoma and CLL session
Francesco Forconi, MD, DM, PhD, FRCPath, University of Southampton, Southampton, UK, gives an overview of two abstracts presented at BSH 2022 in the lymphoma and chronic lymphocytic leukemia (CLL) session. Dr Forconi first discusses an abstract presented by Dr Talha Munir and Prof. Peter Hillmen on sudden death and higher rates of cardiac toxicity associated with Bruton’s tyrosine kinase (BTK) inhibitors. Dr Forconi then highlights another session which focused on the effects of the COVID-19 pandemic on CLL patients, and further discusses vaccine responses in these immunosuppressed patients. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
